Essay
age1 published its founding vision essay articulating the firm's thesis: funding contrarian, founder-led companies to increase healthy human lifespan.
Age1
Added recently
Investment
age1 led Loyal's $100M Series C to advance LOY-002, the first FDA-approved longevity drug for extending healthy lifespan in senior dogs. Baillie Gifford and existing investors participated. Loyal has completed safety and efficacy acceptance for FDA Expanded Conditional Approval.
Loyalfordogs
FEB 11, 2026